1
|
Kardaun SH and Jonkman MF: Dexamethasone
pulse therapy for Stevens-Johnson syndrome/toxic epidermal
necrolysis. Acta Derm Venereol. 87:144–148. 2007. View Article : Google Scholar
|
2
|
Hunger RE, Hunziker T, Buettiker U,
Braathen LR and Yawalkar N: Rapid resolution of toxic epidermal
necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol.
116:923–924. 2005. View Article : Google Scholar
|
3
|
Engelhardt SL, Schurr MJ and Helgerson RB:
Toxic epidermal necrolysis: An analysis of referral patterns and
steroid usage. J Burn Care Rehabil. 18:520–524. 1997. View Article : Google Scholar
|
4
|
Guibal F, Bastuji-Garin S, Chosidow O,
Saiag P, Revuz J and Roujeau JC: Characteristics of toxic epidermal
necrolysis in patients undergoing long-term glucocorticoid therapy.
Arch Dermatol. 131:669–672. 1995. View Article : Google Scholar
|
5
|
Schneck J, Fagot JP, Sekula P, Sassolas B,
Roujeau JC and Mockenhaupt M: Effects of treatments on the
mortality of Stevens-Johnson syndrome and toxic epidermal
necrolysis: A retrospective study on patients included in the
prospective EuroSCAR study. J Am Acad Dermatol. 58:33–40. 2008.
View Article : Google Scholar
|
6
|
Moghadam-Kia S and Werth VP: Prevention
and treatment of systemic glucocorticoid side effects. Int J
Dermatol. 49:239–248. 2010. View Article : Google Scholar
|
7
|
Kreft B, Wohlrab J, Bramsiepe I, Eismann
R, Winkler M and Marsch WC: Etoricoxib-induced toxic epidermal
necrolysis: Successful treatment with infliximab. J Dermatol.
37:904–906. 2010. View Article : Google Scholar
|
8
|
Chen LL, Lu DD, Shi X, Sun XD, Xie LX,
Chen XJ, Ding L, Jin WJ and Wang YF: Drug rash with eosinophilia
and systemic symptoms controlled by tumor necrosis factor-α
antagonist: A clinical observation. Zhonghua Pi Fu Ke Za Zhi.
46:621–625. 2013.(In Chinese).
|
9
|
Bastuji-Garin S, Fouchard N, Bertocchi M,
Roujeau JC, Revuz J and Wolkenstein P: SCORTEN: A
severity-of-illness score for toxic epidermal necrolysis. J Invest
Dermatol. 115:149–153. 2000. View Article : Google Scholar
|
10
|
Harr T and French LE: Stevens-Johnson
syndrome and toxic epidermal necrolysis. Chem Immunol Allergy.
97:149–166. 2012. View Article : Google Scholar
|
11
|
Miliszewski MA, Kirchhof MG, Sikora S,
Papp A and Dutz JP: Stevens-Johnson syndrome and toxic epidermal
necrolysis: An analysis of triggers and implications for improving
prevention. Am J Med. 129:1221–1225. 2016. View Article : Google Scholar
|
12
|
Lalosevic J, Nikolic M, Gajic-Veljic M,
Skiljevic D and Medenica L: Stevens-Johnson syndrome and toxic
epidermal necrolysis: A 20-year single-center experience. Int J
Dermatol. 54:978–984. 2015. View Article : Google Scholar
|
13
|
Greenberger PA: Drug allergy. J Allergy
Clin Immunol. 117 2 Suppl Mini-Primer:S464–S470. 2006. View Article : Google Scholar
|
14
|
Waters JP, Pober JS and Bradley JR: Tumour
necrosis factor in infectious disease. J Pathol. 230:132–147. 2013.
View Article : Google Scholar
|
15
|
Stefferl A, Hopkins SJ, Rothwell NJ and
Luheshi GN: The role of TNF-alpha in fever: Opposing actions of
human and murine TNF-alpha and interactions with IL-beta in the
rat. Br J Pharmacol. 118:1919–1924. 1996. View Article : Google Scholar
|
16
|
Nakayama M, Niki Y, Kawasaki T, Takeda Y,
Horiuchi K, Sasaki A, Okada Y, Umezawa K, Ikegami H, Toyama Y and
Miyamoto T: Enhanced susceptibility to lipopolysaccharide-induced
arthritis and endotoxin shock in interleukin-32 alpha transgenic
mice through induction of tumor necrosis factor alpha. Arthritis
Res Ther. 14:R1202012. View
Article : Google Scholar
|
17
|
Doss GP, Agoramoorthy G and Chakraborty C:
TNF/TNFR: Drug target for autoimmune diseases and immune-mediated
inflammatory diseases. Front Biosci (Landmark Ed). 19:1028–1040.
2014. View Article : Google Scholar
|
18
|
Azzawi M, Hasleton PS and Hutchinson IV:
TNF-alpha in acute cardiac transplant rejection. Cytokines Cell Mol
Ther. 5:41–49. 1999.
|
19
|
Esposito E and Cuzzocrea S: TNF-alpha as a
therapeutic target in inflammatory diseases, ischemia-reperfusion
injury and trauma. Curr Med Chem. 16:3152–3167. 2009. View Article : Google Scholar
|
20
|
He M, Dong LM and Hou XB: Time-related
expression of IL-6, IL-8 and TNF-alpha following explosive injury
to rabbit's chest. Fa Yi Xue Za Zhi. 30:85–87. 2014.(In
Chinese).
|
21
|
Paquet P, Nikkels A, Arrese JE,
Vanderkelen A and Piérard GE: Macrophages and tumor necrosis factor
alpha in toxic epidermal necrolysis. Arch Dermatol. 130:605–608.
1994. View Article : Google Scholar
|
22
|
Carr A, Vasak E, Munro V, Penny R and
Cooper DA: Immunohistological assessment of cutaneous drug
hypersensitivity in patients with HIV infection. Clin Exp Immunol.
97:260–265. 1994. View Article : Google Scholar
|
23
|
Nassif A, Bensussan A, Dorothée G,
Mami-Chouaib F, Bachot N, Bagot M, Boumsell L and Roujeau JC: Drug
specific cytotoxic T-cells in the skin lesions of a patient with
toxic epidermal necrolysis. J Invest Dermatol. 118:728–733. 2002.
View Article : Google Scholar
|
24
|
Paul C, Wolkenstein P, Adle H, Wechsler J,
Garchon HJ, Revuz J and Roujeau JC: Apoptosis as a mechanism of
keratinocyte death in toxic epidermal necrolysis. Br J Dermatol.
134:710–714. 1996. View Article : Google Scholar
|
25
|
Viard-Leveugle I, Gaide O, Jankovic D,
Feldmeyer L, Kerl K, Pickard C, Roques S, Friedmann PS, Contassot E
and French LE: TNF-α and IFN-γ are potential inducers of
Fas-mediated keratinocyte apoptosis through activation of inducible
nitric oxide synthase in toxic epidermal necrolysis. J Invest
Dermatol. 133:489–498. 2013. View Article : Google Scholar
|
26
|
Lin YF, Yang CH, Sindy H, Lin JY, Hui
Rosaline CY, Tsai YC, Wu TS, Huang CT, Kao KC, Hu HC, et al: Severe
cutaneous adverse reactions related to systemic antibiotics. Clin
Infect Dis. 58:1377–1385. 2014. View Article : Google Scholar
|
27
|
Strom BL, Carson JL, Halpern AC, Schinnar
R, Snyder ES, Shaw M, Tilson HH, Joseph M, Dai WS, Chen D, et al: A
population-based study of Stevens-Johnson syndrome. Incidence and
antecedent drug exposures. Arch Dermatol. 127:831–838. 1991.
View Article : Google Scholar
|